Wolfgang Mueck

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

Dagmar Kubitza, Michael Becka, Wolfgang Mueck et al. · British Journal of Clinical Pharmacology · 2010 · 426 citations · Full text

Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans

Corinna Weinz, Thomas Schwarz, Dagmar Kubitza et al. · Drug Metabolism and Disposition · 2009 · 373 citations

Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

Wolfgang Mueck, Dagmar Kubitza, Michael Becka · British Journal of Clinical Pharmacology · 2013 · 364 citations · Full text

Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects

Dagmar Kubitza, Michael Becka, Michael Zuehlsdorf et al. · The Journal of Clinical Pharmacology · 2007 · 327 citations

Obesity, Thrombosis, Dose Adjustment +14

Rivaroxaban

Wolfgang Mueck, Anthonie W.A. Lensing, Giancarlo Agnelli et al. · Clinical Pharmacokinetics · 2011 · 323 citations